Immunoglobulin light-chain amyloidosis (AL) is a disease with limited treatment options due to the frailty of patients caused by organ damage. Since the clonal plasma cells often contain the cytogenetic aberration t(11;14), the Bcl-2 inhibitor venetoclax is suggested to have a role in the treatment of AL. Here, we report of a heart-transplanted patient, refractory to multiple therapies, reaching a rapid complete response with single-agent venetoclax.

1.
Warsame
R
,
Kumar
SK
,
Gertz
MA
,
Lacy
MQ
,
Buadi
FK
,
Hayman
SR
, et al
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death
.
Blood Cancer J
.
2015
May
;
5
(
5
):
e310
.
[PubMed]
2044-5385
2.
Bochtler
T
,
Hegenbart
U
,
Cremer
FW
,
Heiss
C
,
Benner
A
,
Hose
D
, et al
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
.
Blood
.
2008
May
;
111
(
9
):
4700
5
.
[PubMed]
0006-4971
3.
Bochtler
T
,
Hegenbart
U
,
Kunz
C
,
Granzow
M
,
Benner
A
,
Seckinger
A
, et al
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens
.
J Clin Oncol
.
2015
Apr
;
33
(
12
):
1371
8
.
[PubMed]
0732-183X
4.
Merlini
G
,
Wechalekar
AD
,
Palladini
G
.
Systemic light chain amyloidosis: an update for treating physicians
.
Blood
.
2013
Jun
;
121
(
26
):
5124
30
.
[PubMed]
0006-4971
5.
Leung
N
,
Thomé
SD
,
Dispenzieri
A
.
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
.
Haematologica
.
2018
Mar
;
103
(
3
):
e135
7
.
[PubMed]
0390-6078
6.
Ghilardi
G
,
Stussi
G
,
Mazzucchelli
L
,
Röcken
C
,
Rossi
D
,
Gerber
B
.
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
.
Amyloid
.
2019
Sep
;
26
(
3
):
173
4
.
[PubMed]
1350-6129
7.
Premkumar
V
,
Comenzo
R
,
Lentzsch
S
.
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
Clin Lymphoma Myeloma Leuk
.
2019
Oct
;
19
(
10
):
686
8
.
[PubMed]
2152-2650
8.
Gran
C
,
Gahrton
G
,
Alici
E
,
Nahi
H
.
Case Report: treatment of light-chain amyloidosis with daratumumab monotherapy in two patients
.
Eur J Haematol
.
2018
Apr
;
100
(
4
):
386
8
.
[PubMed]
0902-4441
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.